Cytokinetics (CYTK) Jefferies 2024 Global Healthcare Conference summary

Strategic and financial updates

• Addressed recent rumors and clarified the context of strategic interest and acquisition discussions, confirming negotiations with a third party that ultimately did not result in a transaction.

• Board and management remain committed to maximizing shareholder value, with ongoing advice from top financial and legal advisors.

• Recent financial transactions secured over $1 billion in capital, including $740 million in immediate cash, balancing equity, debt, revenue sharing, and royalty monetization.

• Access to additional capital from Royalty Pharma provides flexibility and supports commercialization and pipeline advancement.

• The cost of capital from the Royalty Pharma deal is competitive, with a low double-digit interest rate and key optionality.

Pipeline and clinical development

• Strategic priorities include global commercial launch of aficamten, label-expanding trials, and advancing late-stage pipeline assets like omecamtiv and CK-586.

• SEQUOIA-HCM Phase III results for aficamten were positive, meeting all primary and secondary endpoints, supporting a next-in-class opportunity.

• Ongoing and upcoming studies (FOREST, MAPLE, ACACIA, CEDAR) will provide further data on aficamten and pipeline assets.

• Omecamtiv is advancing into a confirmatory Phase III study, with a flexible design and strong regulatory and expert support.

• CK-586 is progressing, with Phase I data expected this year and early human data suggesting potential for no monitoring requirement.

Regulatory and commercialization outlook

• Rolling NDA submission for aficamten planned for Q3, with updates on regulatory interactions and risk mitigation labeling expected this year.

• Commercial launch preparations underway for North America, Europe, and China, with potential approvals anticipated next year.

• Differentiated REMS and risk mitigation profile for aficamten under discussion with FDA, aiming for less burdensome monitoring requirements.

• FOREST study data support a favorable safety and convenience profile, with lower incidence of EF excursions and less frequent echo monitoring.